Phase 2 Lung Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 to 75 years old at the time of signing the consent form
• People whose non-small cell lung cancer (a type of lung cancer) has been confirmed through a tissue or cell sample test
• People whose lung cancer has spread or is locally advanced, has a specific genetic change called a MET abnormality, and has continued to grow after standard treatment
• People who have at least one tumour that can be measured on a scan, as assessed by the study doctor
• People who are in reasonably good physical condition, able to carry out daily activities with little or no limitation, assessed within 7 days before the first dose (confirm with trial site)
• People whose life expectancy is at least 3 months, as assessed by the study doctor
• People whose organs and bone marrow are functioning well enough to meet the trial's requirements
• People who agree to use highly effective contraception throughout the treatment period
• People who are willing to participate voluntarily, sign the consent form, and attend all required visits and follow the study procedures

Who may not be able to join:

• People with active cancer that has spread to the brain, spinal cord, or the lining of the brain, or who have pressure on the spinal cord
• People who have had another type of cancer in the 3 years before the first dose
• People with certain heart or blood vessel conditions, or risk factors for these conditions (confirm with trial site for specific details)
• People with serious or uncontrolled other illnesses
• People with a history of a lung condition called interstitial lung disease, or a history of lung inflammation not caused by infection
• People with severe lung damage caused by lung disease complications
• People at risk of an abnormal connection forming between the oesophagus and the airway or chest cavity, or where the tumour is pressing on or growing into nearby vital organs or blood vessels
• People whose side effects from previous cancer treatments have not improved to a mild level or resolved
• People with active tuberculosis (TB) of the lungs
• People who have had an organ transplant or a stem cell transplant from a donor
• People with active hepatitis B or hepatitis C infection
• People who have tested positive for HIV or have a history of AIDS, or who have an active syphilis infection
• People with a known allergy or sensitivity to the study drug (SKB571) or its ingredients, or a history of severe allergic reaction to similar medicines called monoclonal antibodies
• People who have had major surgery within 4 weeks before the first dose, or who are expected to need major surgery during the study
• People who have had a serious infection within 4 weeks before the first dose
• People who have taken corticosteroids above a certain dose or other immune-suppressing medicines within 2 weeks before the first dose
• People who have received a live vaccine within 30 days before the first dose, or who plan to receive one during the study
• Women who are pregnant or breastfeeding
• People with certain conditions or symptoms not related to cancer but caused by it, or non-cancer-related diseases affecting the whole body (confirm with trial site)
• People with any other condition that the study doctor believes would affect their safety or the reliability of the study results

Important: Always verify eligibility with the trial site directly before applying.